Pavel Gadelgaraevich Tarazov

Prof. Dr. Pavel Gadelgaraevich Tarazov

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1990 in American Journal of Roentgenology
Verified
Journal Article
Open access
PTPavel Gadelgaraevich Tarazov
Pavel Gadelgaraevich Tarazov
VPV N Polysalov
V N Polysalov
VRV K Ryzhkov
V K Ryzhkov
VTV N Polysalov And V K Ryzhkov P G Tarazov
V N Polysalov And V K Ryzhkov P G Tarazov
KEKhaled M. Elsayes
Khaled M. Elsayes
MMMichael M. Maher
Michael M. Maher

18 March 2020 in Grekov's Bulletin of Surgery
Verified
Journal Article
Open access
PDF file
APA. S. Polekhin
A. S. Polekhin
PTPavel Gadelgaraevich Tarazov
Pavel Gadelgaraevich Tarazov
APA. A. Polikarpov
A. A. Polikarpov
DGD. A. Granov
D. A. Granov
OBJECTIVE was to evaluate the results of transcatheter arterial chemoembolization (TACE) in the treatment of patients with hepatocellular carcinoma (HCC) on advanced liver cirrhosis (LC) and intermediate stage (B) according to BCLC classification (Barcelona Clinic Liver Cancer classification).METHODS AND MATERIALS. We evaluated results of TACE in 54 patients. Of them, 12 (22 %) had stage A of cirrhosis and 42 (78 %) – stage B of cirrhosis according to the Child-Pugh score. Nine (17 %) patients matched stage A4 and 45 (83 %) – stage В according to BCLC classification. The TACEs was performed according to the conventional practice with using Lipiodol + gelfoam (n=40) and with a drug-eluting beads (n=14) from 1 to 16 (average 6) times. The Doxorubicin was used as a first-line therapy in all cases.RESULTS. After TACE, two patients died of liver failure (3.7 %). According to the m-RECIST, complete response to treatment was observed in 9 (16.5 %), partial response – in 13 (24 %), stabilization – in 19 (35.5 %) and progression – in 13 (24 %) patients. At present, 22 (41 %) patients are alive for 1 to 51 (average 16.2) months. 32 patients (59 %) died between 2 to 62 months: 13 (24 %) – from HCC progression, 19 (35 %) – from liver failure. The 1– 2–3-year survival rate was 75–44–15 %; only one patient survived > 5 years. The median survival rate was (22.0±3.0) months, overall survival rate according to Kaplan – Meier was 26 months.CONCLUSION. TACE is a relatively safe and effective treatment in patients with HCC on advanced LC and intermediate stage (B).

22 September 2019 in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Verified
Journal Article
Closed access
AKA. V. Kozlov
A. V. Kozlov
DGD. A. Granov
D. A. Granov
PTPavel Gadelgaraevich Tarazov
Pavel Gadelgaraevich Tarazov
APA. V. Pavlovskiy
A. V. Pavlovskiy
LKL. I. Korytova
L. I. Korytova
ERE. V. Rozengauz
E. V. Rozengauz
Objective. To study effectiveness of intra-arterial chemotherapy in patients with locally advanced and metastatic pancreatic cancer.Material and methods. There were 329 patients who underwent regional chemotherapy in 2000 – 2015 (infusion through celiac trunk – 167, chemoembolization of gastroduodenal artery – 52, combination of these methods – 72, combined chemo-radiotherapy – 38). Locally advanced unresectable pancreatic cancer with arterial invasion (T4 grade) was observed in 198 (60.2%) patients, liver metastases (stage IV) – in 131 (39.8%) patients. Chemoembolization or chemoradiation therapy was performed for patients without distant metastases.Results. The best results for unresectable pancreatic cancer were obtained in 160 patients after chemoembolization combined with infusion. Partial response was obtained in 24.1% of cases compared with 8.9% and 13.4% of cases after infusion or chemoembolization alone. Mean life expectancy was 15.5 months compared with 14.6 and 10.6 months, respectively. Median of life expectancy was 15.6 months compared with 11.7 and 10.8 months, respectively. At the same time, progression of disease was observed in the majority of 131 patients with metastatic cancer. Partial response was noted only in 2.3% of patients only after chemoinfusion. Survival and median survival after chemoinfusion and combination of chemoembolization with chemoinfusion were similar (10.1 (8.3) and 10.9 (7.5) months). Chemoradiotherapy in 4 patients with initially unresectable pancreatic cancer resulted reduction of tumor dimension by 28% (24–32%). Therefore, radical operations were performed later. One-year survival was achieved in 20 (58.8%) out of 34 patients with unresectable pancreatic cancer. Mean life expectancy was 15.4 months (median 13.8 months).Conclusion. Intra-arterial chemotherapy is effective treatment in patients with pancreatic cancer stage III and IV. Combination of celiac axis infusion with arterial embolization, as well as infusion with radiotherapy resulted the best survival. Certain advantage of chemoinfusion was found for liver metastases. The use of new chemotherapy modes for intra-arterial infusion requires further study.

13 February 2003
Verified
Journal Article
Closed access
AKA V Kozlov
A V Kozlov
APA A Polikarpov
A A Polikarpov
NON V Oleshchuk
N V Oleshchuk
PTPavel Gadelgaraevich Tarazov
Pavel Gadelgaraevich Tarazov

8 November 2020 in Grekov's Bulletin of Surgery
Verified
Journal Article
Open access
PDF file
ДГД. Ан. Гранов
Д. Ан. Гранов
APA. A. Polikarpov
A. A. Polikarpov
PTPavel Gadelgaraevich Tarazov
Pavel Gadelgaraevich Tarazov
ИТИ. Вл. Тимергалин
И. Вл. Тимергалин
VPV. N. Polysalov
V. N. Polysalov
Опухоль Клатскина, осложненная механической желтухой и холангитом, в реальной практике: нерезектабельная опухоль или инкурабельный пациент?

15 May 2022 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
AKA. V. Kozlov
A. V. Kozlov
PTPavel Gadelgaraevich Tarazov
Pavel Gadelgaraevich Tarazov
APA. A. Polikarpov
A. A. Polikarpov
AMA. V. Moiseenko
A. V. Moiseenko
AUA. I. Urbansky
A. I. Urbansky
DGD. A. Granov
D. A. Granov
Aim. To evaluate the safety and accuracy of percutaneous transhepatic biliary biopsy in patients with suspected Klatskin tumor.Materials and methods. Between 2013–2020, percutaneous transhepatic biliary drainage (PTBD) was performed in 52 patients with Klatskin tumor, complicated by obstructive jaundice. After successful PTBD, the diagnosis was verified by antegrade access. 74 procedures were performed: brush (n = 36; 48.6 %) or forceps biopsies (n = 38; 51.4 %).Results. There were no adverse events associated with a brush biopsy. Only grade I complications were after the forceps technique: 3 patients (7.9 %) developed hemobilia, which was corrected conservatively. Malignant lesions of the biliary tract were detected by forceps technique in 79.0 %, brush biopsy in 66.7 % (p >0,05). The degree of tumor differentiation was determined in 60.0 % (n = 18) vs 12.5 % (n = 3) (p < 0,01), respectively.Sensitivity and specificity of forceps biopsy were slightly higher than in brush: 82.4 % and 75.0 % vs 73.3 % and 66.7 % (p >0,05).Conclusions. Antegrade percutaneous transhepatic biliary biopsy is safe for both brush and forceps techniques. However, forceps biopsy has higher sensitivity and specificity in the diagnosis Klatskin tumor and better possibility of determining the degree of malignancy differentiation.